# US 2022/0034872 A1 · Composition comprising material for regulating oct4 modification to repress stemness

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0034872 A1
- Document ID: US20220034872A1
- Status: Published application
- Kind: A1
- Application number: 17/285,710
- Filed: 2018-12-06
- Published: 2022-02-03
- Earliest claimed: 2018-10-31
- Assignees: National Cancer Center
- Applicants: National Cancer Center
- Inventors: Hyonchol JANG; Dong Keon KIM
- Web page: https://patentgrep.com/patent/US20220034872A1

## CPC

- G01N 33/5073: {Stem cells}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 16/18: against material from animals or humans
- G01N 33/6854: {Immunoglobulins}
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- G01N 2440/14: phosphorylation
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to a composition for repressing the sternness of stem cells, which comprises a material for regulating OCT4 modification. The material for regulating OCT4 modification according to the present invention may regulate the phosphorylation or methylation of OCT4 and inhibit Wnt signaling, thereby effectively reducing the sternness of various stem cells. Therefore, since it can be effectively used in inhibition of proliferation, recurrence and metastasis of cancer, and inhibition of resistance to an anticancer agent, and can reduce sternness even in normal stem cells, it is expected that the time for differentiation of embryonic stem cells into specific cells is shortened, and efficiency is increased.

## Claims

### Claim 1

A method of inhibiting stemness through regulation of OCT4 modification in vitro, comprising any one or mere selected from the group consisting of the following:
(a) phosphorylating serine 281 in the amino acid sequence of mouse octamer-binding transcription factor 4 (OCT4) or serine 288 in the amino acid sequence of human OCT4:
(b) inhibiting the methylation of arinine 179 in the amino acid sequence of mouse OCT4, arginine 186 in the amino acid sequence of human OCT4, lysine 215 in the amino acid sequence of mouse OCT4, or lysine 222 in the amino acid sequence of human OCT4; and
(c) inhibiting the phosphorylation of Serine 351 in the amino acid sequence of mouse OCT4 or serine 359 in the amino acid sequence of human OCT4.

### Claim 2 (depends on 1)

The method according to claim 1, further comprising:
in the inhibiting (c), blocking the activation of Wnt signaling.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the amino acid sequence of mouse OCT4 is represented by an amino acid sequence of SEQ ID NO: 1.

### Claim 4 (depends on 1)

The meth according to claim 1, wherein the amino acid sequence of human OCT4 is represented by an amino acid sequence of SEQ ID NO: 2.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the stem cells are any one selected from the group consisting of embryonic stem cells, gametes, and cancer stem cells.

### Claim 6

A method of regulating stemness through regulation of the function of OCT4 modification in vitro, comprising:
inhibiting the phosphorylation of serine 351 in the amino acid sequence of mouse octamer-binding transcription factor 4 (OCT4) or serine 359 in the amino acid sequence of human OCT4; and
activating Wnt signaling.

### Claim 7

An antibody for detecting whether serine 351 in the amino acid sequence of mouse octamer-binding transcription factor 4 (OCT4) or serine 359 in the amino acid sequence of human OCT4 is phosphorylated,
wherein the antibody recognizes an epitope represented by an amino acid sequence of SEO ID NO: 7 or 8 and specifically binds to phosphorylated serine 351 of mouse OCT4 or phosphorylated serine 359 of human OCT4.

### Claim 8

A method of screening a material for repressing the stemness of stem cells, comprising:
(a) treating cells expressing mouse octamer-binding transcription factor 4 (OCT4) or human OCT4 with a candidate material;
(b) detecting any one or more selected from the group consisting of the phosphorylation of serine 281 in the amino acid sequence of mouse OCT4 or serine 288 in the amino acid sequence of human OCT4, the methylation of arginine 179 in the amino acid sequence of mouse OCT4, arginine 186 in the amino acid sequence of human OCT4, lysine 215 in the amino acid sequence of mouse OCT4, or lysine 222 in the amino acid sequence of human OCT4, and the phosphorylation of serine 351 in the amino acid sequence of mouse OCT4 or serine 359 in the amino acid sequence of human OCT4; and
(c) selecting the candidate material as a material for repressing the stemness of stem cells when serine 281 in the amino acid sequence of mouse OCT4 or serine 288 in the amino acid sequence of human OCT4 is phosphorvlated, when the methylation of arginine 179 in the amino acid sequence of mouse OCT4, arginine 186 in the amino acid sequence of human OCT4, lysine 215 in the amino acid sequence of mouse OCT4, or lysine 222 in the amino acid sequence of human OCT4 is inhibited, or when the phosphorylation of serine 351 in the amino acid sequence of mouse OCT4 or serine 359 in the amino acid sequence of human OCT4 is inhibited.

### Claim 9 (depends on 8)

The method according to claim 8, comprising:
detecting whether Wnt signaling is activated in cells as the detecting (b); and
selecting the candidate material as a material for repressing the sternness of stem cells when the Wnt signaling is not activated as the selecting (c).

### Claim 10

A method of diagnosing whether the stemness of stem cells is repressed, comprising:
(a) detecting any one or more selected from the group consisting of the phosphorylation of serine 281 in the amino acid sequence of mouse octamer-binding transcription factor 4 (OCT4) or serine 288 in the amino acid sequence of human OCT4, the methylation of arginine 179 in the amino acid sequence of mouse OCT4, arginine 186 in the amino acid sequence of human OCT4, lysine 215 in the amino acid sequence of mouse OCT4, or lysine 222 in the amino acid sequence of human OCT4, and the phosphorylation of serine 351 in the amino acid sequence of mouse OCT4 or serine 359 in the amino acid sequence of human OCT4; and
(b) determining that the stemness of stem cells is repressed when serine 281 in the amino acid sequence of mouse OCT4 or serine 288 in the amino acid sequence of human OCT4 is phosphorylated, when the methylation of arginine 179 in the amino acid sequence of mouse OCT4, arginine 186 in the amino acid sequence of human OCT4, lysine 215 in the amino acid sequence of mouse OCT4, or lysine 222 in the amino acid sequence of human OCT4 is inhibited, or when the phosphorylation of serine 351 in the amino acid sequence of mouse OCT4 or serine 359 in the amino acid sequence of human OCT4 is inhibited.

### Claim 11 (depends on 10)

The method according to claim 10, comprising:
confirming whether Wnt signaling is activated in cells expressing mouse OCT4 or human OCT4 as the detecting (a); and
determining that the stemness of stem cells is repressed when the Wnt signaling is not activated as the determining (b).

### Claim at position 12

12-29. (canceled)
